Cholangiocarcinoma and Primary sclerosing cholangitis

On February 15, World Cholangiocarcinoma Day!


Today we would like to introduce cholangiocarcinoma (CCA, bile duct cancer) and its risk factor, primary sclerosing cholangitis (PSC).


CCA is the second most common liver cancer after hepatocellular carcinoma, and its incidence appears to be increasing worldwide (Banales JM et al., Nat Rev Gastroenterol Hepatol. 2020).

CCA is a rare cancer have been increasing in the past few decades worldwide, representing a global health problem. Despite advances in CCA awareness, knowledge, diagnosis and therapies, patient prognosis has not improved substantially in the past decade, with 5-year survival (7–20%).


PSC is involved in the development of CCA.

The annual incidence of CCA in patients with PSC is estimated to be 0.5%-1.5%, with a reported lifetime incidence of 20% (Fung BM, et al. World J Gastroenterol. 2019).

Therefore, prevention or treatment strategies for PSC may potentially help resolve CCA, and PSC is an important disease to resolve. Currently, there are no PSC drugs on the market, and the development of new drugs is important.


PSC is a progressive disease of unknown cause that progresses from cholangitis to cirrhosis due to bile stasis associated with narrowing and dilation of the intra- and extrahepatic bile ducts with fibrosis.


SMC can conduct drug efficacy evaluation studies of DDC model of PSC, which may be useful in the research and development of PSC.

Below are some of the advantages of using the DDC model for developing potential treatments for PSC:


–  develops obstructed bile ducts, brisk ductular proliferation and intense pericholangitis that is associated with ‘onion skin’ periductal fibrosis

–  has a higher survival rate and disease correlation than the BDL model

–  reproduces major histopathological features observed in human cholestatic liver disease

–  human biomarkers associated with PSC, such as an increase in ALT, AST and bilirubin, can be observed


If you are interested in the PSC model or our services, please do not hesitate to contact us.



World Cholangiocarcinoma Day 【 Link

Contact us 【 Click here